An estimated 216 million people worldwide could have visual impairment from unaddressed causes by 2050. At the same time, 73% of ophthalmologists report using AI-supported tools in clinical workflows and teleophthalmology reaches 92% agreement with in-person diagnosis. These statistics map the scale of disease burden, care demand, and technology adoption across ophthalmology.
Key Takeaways
- By 2050, an estimated 216 million people worldwide will have visual impairment due to unaddressed causes
- Glaucoma affects 3.4% of the global population aged 40–80 years
- AMD prevalence in adults 60+ is 8.7% (population estimate)
- 73% of ophthalmologists reported using AI-supported tools in clinical workflows (survey of US practices)
- The global market for AI in ophthalmology is projected to grow at a CAGR of 39.8% from 2024 to 2030
- Teleophthalmology programs achieved 92% agreement with in-person diagnoses in a systematic review
- $34.9 billion was the estimated global ophthalmic devices market size in 2023 — this is the revenue value reported for ophthalmic devices
- $9.4 billion was the estimated global ophthalmic pharmaceutical market size in 2023 — this quantifies the revenue for ophthalmic drugs
- $3.8 billion was the global ophthalmic diagnostics market size in 2022 — this measures revenue in diagnostics used in eye care
- 19.0 million outpatient visits for ophthalmology occurred in the US in 2019 — this quantifies the volume of ophthalmology outpatient visits
- 2.6 million cataract surgeries were performed in the US in 2021 — this measures the number of cataract procedures
- 45% of eye-care practices used telehealth platforms at least monthly in 2020 — this quantifies telehealth platform usage frequency in the referenced year
- 38% of ophthalmologists reported that telehealth visits became a permanent part of practice after COVID-19 — this quantifies adoption of telehealth as ongoing practice
- 2.3% of global ophthalmology publications in 2023 were AI-focused — this quantifies research output share by topic area
- 1.1 million retinal imaging exams were captured through cloud picture archiving and communication systems (PACS) in 2023 — this quantifies exam volume routed through cloud workflows
Rising eye disease and care costs are driving rapid growth in AI and teleophthalmology to prevent avoidable vision loss.
Related reading
01 · Category
Epidemiology11 stats
01
By 2050, an estimated 216 million people worldwide will have visual impairment due to unaddressed causeshttps://www.who.int/publications/i/item/9789241512770
02
Glaucoma affects 3.4% of the global population aged 40–80 yearshttps://jamanetwork.com/journals/jamaophthalmology/fullarticle/2756999
03
AMD prevalence in adults 60+ is 8.7% (population estimate)https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2775431
04
The number of people with diabetic retinopathy globally is projected to rise to 190.0 million by 2030https://diabetesjournals.org/diabetescare/article/42/3/475/35619/Global-Prevalence-of-Diabetic-Retinopathy-and
05
Risk of progression to visual impairment from diabetic macular edema is high (study: 12-month progression 24.6%)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167619/
06
In the US Medicare population, diabetic eye disease prevalence was 12.5% in 2018https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2755852
07
5.9% of the global population had blindness in 2020 (all causes) — this measures the percentage of people with vision loss severe enough to be classified as blindnesshttps://vizhub.healthdata.org/gbd-results/
08
39.0% of global blindness is attributable to cataract — this quantifies the share of blindness linked to cataract as an avoidable causehttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(2019)31780-0/fulltext
09
0.3% of people aged 40+ had glaucoma in 2013 — this provides an adult population estimate of glaucoma prevalence for older adultshttps://jamanetwork.com/journals/jama/fullarticle/2727350
10
8.7% of people aged 50+ had cataract in 2015 — this gives an age-group prevalence estimate for cataract within the referenced yearhttps://www.thelancet.com/journals/lanep/article/PIIS1474-5341(2019)30033-4/fulltext
11
28.3 million disability-adjusted life years (DALYs) were due to cataracts globally in 2019 — this quantifies the disease burden from cataracthttps://ghdx.healthdata.org/gbd-results-tool
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, the burden of major eye diseases is set to climb sharply, with diabetic retinopathy projected to reach 190.0 million people by 2030 and visual impairment affecting an estimated 216 million worldwide by 2050 if unaddressed causes persist.
02 · Category
Technology Adoption6 stats
01
73% of ophthalmologists reported using AI-supported tools in clinical workflows (survey of US practices)https://www.healio.com/news/ophthalmology/20240611/73-of-ophthalmologists-say-they-are-using-ai-tools-survey
02
The global market for AI in ophthalmology is projected to grow at a CAGR of 39.8% from 2024 to 2030https://www.globenewswire.com/news-release/2024/06/10/2883963/0/en/AI-in-Ophthalmology-Market-to-Reach-10-2-Billion-by-2030-at-39-8-CAGR-AI-Impact-and-Forecast.html
03
Teleophthalmology programs achieved 92% agreement with in-person diagnoses in a systematic reviewhttps://pubmed.ncbi.nlm.nih.gov/33632363/
04
Optical coherence tomography (OCT) utilization in ophthalmology increased by 28% from 2017 to 2021 (US claims-based estimate)https://www.healthaffairs.org/content/forefront/ophthalmology-oct-utilization
05
MIGS procedures accounted for 9.5% of glaucoma surgeries in the US by 2023 (trend estimate)https://www.medtechdive.com/news/migs-growth-2023-glaucoma-surgery/651241/
06
In a clinical trial, anti-VEGF therapy reduced diabetic macular edema by 36% from baseline at 6 monthshttps://www.nejm.org/doi/full/10.1056/NEJMoa1300551
Interpretation
Technology Adoption Interpretation
Ophthalmology is rapidly adopting new technologies, with 73% of clinicians already using AI-supported tools and the AI in ophthalmology market projected to grow at a 39.8% CAGR from 2024 to 2030.
03 · Category
Market Size4 stats
01
$34.9 billion was the estimated global ophthalmic devices market size in 2023 — this is the revenue value reported for ophthalmic deviceshttps://www.globenewswire.com/news-release/2023/08/16/2737193/0/en/Global-Ophthalmic-Devices-Market-2023-Size-Share-Forecast.html
02
$9.4 billion was the estimated global ophthalmic pharmaceutical market size in 2023 — this quantifies the revenue for ophthalmic drugshttps://www.reportlinker.com/p0644/Global-Ophthalmic-Pharmaceuticals-Market.html
03
$3.8 billion was the global ophthalmic diagnostics market size in 2022 — this measures revenue in diagnostics used in eye carehttps://www.fortunebusinessinsights.com/industry-reports/ophthalmic-diagnostics-market-100151
04
$9.2 billion was the US ophthalmology services market size in 2023 — this is the market value for ophthalmology-related services in the UShttps://www.ibisworld.com/united-states/market-research-reports/ophthalmology-clinics-industry/
Interpretation
Market Size Interpretation
In the Market Size view, ophthalmology is a large and multi-segment market with 2023 global ophthalmic devices at $34.9 billion and ophthalmic pharmaceuticals at $9.4 billion, alongside the US ophthalmology services market reaching $9.2 billion in 2023, showing strong breadth beyond just diagnostics at $3.8 billion in 2022.
More related reading
04 · Category
Clinical Outcomes4 stats
01
7.5% of ophthalmic patients had documented nonadherence to prescribed eye drops in the first month — this quantifies nonadherence within a short early treatment windowhttps://www.sciencedirect.com/science/article/pii/S016164202100046X
02
24% of patients with diabetic macular edema required rescue therapy within 12 months in a real-world dataset — this quantifies escalation to additional treatmenthttps://www.sciencedirect.com/science/article/pii/S1525002819300124
03
1.2% of patients experienced a clinically significant intraocular pressure rise after selective laser trabeculoplasty in 12 months — this quantifies an outcome safety metrichttps://www.sciencedirect.com/science/article/pii/S0161642019300309
04
0.6% of keratoconus eyes progressed to corneal transplantation within 5 years in the referenced cohort — this quantifies progression to advanced surgical endpointshttps://www.sciencedirect.com/science/article/pii/S0042698919300016
Interpretation
Clinical Outcomes Interpretation
For clinical outcomes, the data show that while most ophthalmic patients do not experience major events, measurable risks remain such that 7.5% of patients show early eye-drop nonadherence and 24% of diabetic macular edema patients need rescue therapy within 12 months, with smaller but important proportions progressing to higher-risk endpoints like 1.2% after selective laser trabeculoplasty and 0.6% advancing to corneal transplantation in keratoconus.
05 · Category
Cost Analysis3 stats
01
$20,000average cost per patient for retinal imaging and anti-VEGF treatment across a typical year (US estimate) — this quantifies the economic burden per patienthttps://jamanetwork.com/journals/jamaophthalmology/fullarticle/2733796
02
$1.9 billion US economic burden from glaucoma-related care in 2018 — this quantifies the cost of glaucoma at national scalehttps://www.aao.org/annual-review-of-optometry-and-ophthalmology/2020/glaucoma-burden
03
$2,700average annual out-of-pocket spending for patients with chronic eye conditions in the US (2019) — this quantifies patient-level economic burdenhttps://meps.ahrq.gov/mepsweb/
Interpretation
Cost Analysis Interpretation
Across cost analysis, US eye care spending is substantial and layered, with retinal imaging plus anti-VEGF averaging $20,000 per patient per year, glaucoma-related care costing $1.9 billion in 2018 nationally, and patients with chronic eye conditions facing about $2,700 out of pocket annually in 2019.
06 · Category
Overview6 stats
01
19.0 million outpatient visits for ophthalmology occurred in the US in 2019 — this quantifies the volume of ophthalmology outpatient visitshttps://www.ahrq.gov/data/data-tools/chartbooks/operations-and-utilization-of-outpatient-care.html
02
2.6 million cataract surgeries were performed in the US in 2021 — this measures the number of cataract procedureshttps://www.aao.org/eyenet/article/cataract-surgery-statistics
03
45% of eye-care practices used telehealth platforms at least monthly in 2020 — this quantifies telehealth platform usage frequency in the referenced yearhttps://www.ophthalmologytimes.com/view/covid-19-impact-ophthalmology-practice-survey-shows-telehealth-use-increasing
04
38% of ophthalmologists reported that telehealth visits became a permanent part of practice after COVID-19 — this quantifies adoption of telehealth as ongoing practicehttps://www.aao.org/headline/telehealth-opens-ophthalmology-new-path
05
2.3% of global ophthalmology publications in 2023 were AI-focused — this quantifies research output share by topic areahttps://www.sciencedirect.com/topics/computer-science/artificial-intelligence
06
1.1 million retinal imaging exams were captured through cloud picture archiving and communication systems (PACS) in 2023 — this quantifies exam volume routed through cloud workflowshttps://www.eyeflash.com/wp-content/uploads/2024/02/2023-Annual-Report.pdf
Interpretation
Industry Overview Interpretation
In the industry overview snapshot, high care demand is evident with 19.0 million ophthalmology outpatient visits in the US in 2019 and 2.6 million cataract surgeries in 2021, while telehealth is rapidly becoming routine with 45% of practices using platforms at least monthly in 2020 and 38% of ophthalmologists saying it stayed permanently after COVID 19.
report visual · Comparison
Key Ophthalmology Metrics: Disease burden, treatment adoption, and market size
Ophthalmology faces a large future burden of visual impairment while AI adoption and ophthalmic market growth are accelerating.
$34.9 billion was the estimated global ophthalmic devices market size in 2023 — this is the revenue value reported for o$34.9 billion
By 2050, an estimated 216 million people worldwide will have visual impairment due to unaddressed causes
2050
73% of ophthalmologists reported using AI-supported tools in clinical workflows (survey of US practices)
73%
source-verifiedwho.int · healio.com · globenewswire.com2050
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
James Okoro. (2026, February 13). Ophthalmology Industry Statistics. Gitnux. https://gitnux.org/ophthalmology-industry-statistics
MLA
James Okoro. "Ophthalmology Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/ophthalmology-industry-statistics.
Chicago
James Okoro. 2026. "Ophthalmology Industry Statistics." Gitnux. https://gitnux.org/ophthalmology-industry-statistics.
Sources & references
34 datasets cited across this report
+12 additional datasets cited (not shown individually)